// App-Quantinova.ai

TCT-75 : Impact of the Timing of P2Y12 Inhibitor Discontinuation Prior to CABG in Patients with Left Main Disease: Results from the EXCEL Trial

Researchers

Presenter

  • Christopher Kelly

Principal Investigators

  • A. Pieter Kappetein

  • Joseph Sabik

  • William Brown

  • Piet Willem Boonstra

  • Yiran Zhang

  • Patrick Serruys

  • Gregg Stone

Medical Centers

  • Cardiovascular Research Foundation, New York, New York, United States

  • Piedmont Heart Institute CardioThoracic Surgeons, Atlanta, Georgia, United States

  • Medisch Centrum Leeuwarden, Heart Center, Leeuwarden PObox 888, Netherlands

  • Department of Cardiothoracic Surgery, Erasmus University Medical Center, Rotterdam, Netherlands

  • Imperial College, London, United Kingdom

  • Department of Thoracic and Cardiovascular Surgery, The Cleveland Clinic Foundation, Cleveland, Ohio, United States

  • Columbia University, New York, New York, United States

  • Cardiovascular Research Foundation, Columbia University Medical Center/NewYork-Presbyterian Hospital, New York, New York, United States

Locations

  • United States

  • Netherlands

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

  • Cardiovascular (CVS)

Disease

  • Left main disease

  • Stroke

Biomarkers

  • N/A

Drug/Treatment

  • Clopidogrel bisulfate

  • Ticagrelor

  • Prasugrel

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved